Erk Expression
Erk Expression - Related Videos
08:40
Spatial and Temporal Analysis of Active ERK in the C. elegans Germline
0 Views •
Cited by 23 •
2016
We present an immunofluorescence imaging-based method for spatial and temporal localization of active ERK in the dissected C. elegans gonad. The protocol described here can be adapted for visualization of any signaling or structural protein in the C. elegans gonad, provided a suitable antibody reagent is available.
07:55
Subcellular Fractionation for ERK Activation Upon Mitochondrial-derived Peptide Treatment
0 Views •
Cited by 6 •
2017
This protocol describes how to stimulate cells with mitochondrial-derived peptides and assess the signaling cascade and localization of phospho-proteins.
09:58
An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence
0 Views •
2025
RASopathies are multisystem genetic syndromes caused by RAS-MAPK pathway hyperactivation. Potentially pathogenic variants awaiting validation emerge continuously while poor preclinical evidence limits therapy. Here, we describe our in vivo protocol to test and cross-validate RASopathy-associated ERK activation levels and its pharmacological modulation during embryogenesis by live FRET imaging in Teen-reporter zebrafish.
10:34
Using an Automated Cell Counter to Simplify Gene Expression Studies: siRNA Knockdown of IL-4 Dependent Gene Expression in Namalwa Cells
0 Views •
Cited by 2 •
2010
This procedure describes a quick and easy workflow to introduce siRNA into difficult to transfect cell lines and follow gene expression by real-time PCR. Use of an automated cell counter, multi-well electroporation plate, and automated electrophoresis station provide quick and reliable results without the need for expensive robotic handling.
11:48
Grafting of Beads into Developing Chicken Embryo Limbs to Identify Signal Transduction Pathways Affecting Gene Expression
0 Views •
Cited by 3 •
2016
By grafting beads soaked in growth factors or specific inhibitors of signaling pathways into developing embryos it is possible to directly test their effects in vivo. In this protocol beads are grafted into the limb bud to determine the effects of these molecules on gene expression and signal transduction.
FAQs
Total ERK measurement primarily reflects how much ERK protein is present, whereas phosphorylated ERK reports the fraction receiving activation through MEK. These signals can change independently: a sample may contain substantial ERK without equivalent pathway activity, or show altered activation despite similar abundance. Pairing both measurements therefore prevents researchers from treating protein quantity as a direct substitute for signaling output.
Growth-factor input is transmitted through receptor-linked RAS–RAF–MEK signaling, placing MEK upstream of ERK activation. MEK phosphorylates ERK, and activated ERK can then influence targets in both the nucleus and cytoplasm. This sequence matters experimentally because an observed change in ERK-associated signaling may reflect altered upstream transmission or altered ERK abundance, rather than a single regulatory event.
ERK levels are shaped by gene transcription and protein turnover, so abundance reflects more than immediate pathway stimulation. Changes in production can raise or lower the pool available for activation, while turnover changes can alter how long that pool persists. Accounting for these controls helps separate regulation of ERK quantity from regulation of its phosphorylation state in cancer-related signaling studies.
Measuring ERK expression together with ERK phosphorylation creates a two-dimensional view of the pathway: one readout addresses protein abundance, and the other addresses activation status. Comparing the pair can reveal whether a cancer-associated change is mainly quantitative, signaling-related, or involves both. That distinction improves interpretation of experiments examining pathway regulation and cellular responses.
In tumor studies, these measurements can be related to tumor growth, therapeutic response, and resistance. A change in total ERK may indicate altered pathway capacity, whereas a change in phosphorylated ERK indicates altered signaling activity. Evaluating both gives researchers a basis for asking whether treatment or disease-associated behavior coincides with reduced abundance, reduced activation, or persistent pathway signaling.
ERK expression analyses support biomarker development when abundance and phosphorylation are considered together. The combined pattern may help characterize tumors with dysregulated MAPK signaling and provide context for interpreting responses to therapy. It does not identify a single outcome by itself; rather, it supplies molecular measurements that can be compared with malignant progression or treatment-related findings.